Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Cited by (1,011)

Items 701–800 of 1,011

1. Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients
   Haiying Zhang, Yuyuan Jia, Ying Ji, Cong Xu, Yan Liu, Ruifeng Yang, Xiangsha Kong, Yijun Shi, Ling Zhu, Zhenyu Wang et al. · 2022 · Frontiers in Microbiology
2. Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2
   Aleksei Titov, Regina Shaikhutdinova, Olga V. Shcherbakova, Yana V. Serdyuk, Savely A. Sheetikov, Ksenia V. Zornikova, Alexandra Vladimirovna Maleeva, Alexandra A. Khmelevskaya, Dmitry Vladimirovich Dianov, Naina T. Shakirova et al. · 2022 · JCI Insight
3. Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors
   Roberta Rovito, Matteo Augello, Assaf Ben-Haim, Valeria Bono, Antonella d’Arminio Monforte, Giulia Carla Marchetti · 2022 · Frontiers in Immunology
4. Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response
   Jernej Pušnik, Julia König, Karola Mai, Enrico Richter, Jasmin Zorn, Hannah Proksch, Bianca Schulte, Galit Alter, Hendrik Streeck · 2022 · Journal of Virology
5. Characteristics of hospitalized patients with SARS-CoV-2 infection during successive waves of the COVID-19 pandemic in a reference hospital in Spain
   Simona Mihaela Iftimie, Ana Felisa López-Azcona, Maria José Lozano‐Olmo, Anna Hernández‐Aguilera, Salvador Sarrà-Moretó, Jorge Joven, Jordi Camps, Antoni Castro · 2022 · Scientific Reports
6. Longitudinal single-cell analysis of SARS-CoV-2–reactive B cells uncovers persistence of early-formed, antigen-specific clones
   Lydia Scharf, Hannes Axelsson, Aikaterini Emmanouilidi, Nimitha R. Mathew, Daniel J. Sheward, Susannah Leach, Pauline Isakson, Ilya Valerevich Smirnov, Emelie Marklund, Nicolae Miron et al. · 2022 · JCI Insight
7. SARS-CoV-2 and the host-immune response
   David P. Maison, Youping Deng, Mariana Gerschenson · 2023 · Frontiers in Immunology
8. Tracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine
   Felipe Lopes de Assis, Kenneth B. Hoehn, Xiaozhen Zhang, Lela Kardava, Connor D. Smith, Omar El Merhebi, Clarisa M. Buckner, Krittin Trihemasava, Wei Wang, Catherine A. Seamon et al. · 2023 · Cell Reports
9. SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies
   Thomas Theo Brehm, Susanne Pfefferle, Ronald von Possel, Robin Kobbe, Dominik Sebastian Nörz, Stefan Schmiedel, Adam T. Grundhoff, Flaminia Olearo, Petra Emmerich, Alexis Robitaille et al. · 2021 · Viruses
10. Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey
    Lara Esteves Coelho, Paula M. Luz, Débora Castanheira, Emília Moreira Jalil, Hugo Perazzo, Thiago S. Torres, Sandra Wagner Cardoso, Eduardo Mesquita Peixoto, Sandro Nazer, Eduardo Massad et al. · 2022 · The Lancet Regional Health - Americas
11. SIR economic epidemiological models with disease induced mortality
    Aditya Goenka, Lin Liu, Manh‐Hung Nguyen · 2021 · Journal of Mathematical Economics
12. Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines
    Ahmed Sayed Abdel-Moneim, Elsayed M. Abdelwhab, Ziad Ahmed Memish · 2021 · Virology
13. AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 Emergency Use Authorization and Laboratory-Developed Test Serologic Testing in Clinical Laboratories
    Y Victoria Zhang, Joesph R Wiencek, Qing H. Meng, Elitza S. Theel, Nikolina Babić, Lusia Sepiashvili, Nicole Pecora, Patricia R. Slev, Andrew Cameron, Danijela Konforte · 2021 · Clinical Chemistry
14. COVID-19 re-infection in Shahroud, Iran: a follow-up study
    Fariba Zare, Maryam Teimouri, Ahmad Khosravi, Marzieh Rohani-Rasaf, Reza Chaman, Ali Hosseinzadeh, Hozhabr Jamali Atergeleh, Ehsan Binesh, Mohammad Hassan Emamian · 2021 · Epidemiology and Infection
15. Immune profiling of COVID-19: preliminary findings and implications for the pandemic
    Holden Terry Maecker · 2021 · Journal for ImmunoTherapy of Cancer
16. Scientists have favorable opinions on immunity certificates but raise concerns regarding fairness and inequality
    Iván Aranzales, Ho Fai Chan, Reiner Eichenberger, Rainer Hegselmann, David Stadelmann, Benno Torgler · 2021 · Scientific Reports
17. Human Milk Antibodies Against SARS-CoV-2: A Longitudinal Follow-Up Study
    Hannah G. Juncker, Michelle Romijn, Veerle N. Loth, Tom G. Caniels, Christianne J.M. de Groot, Dasja Pajkrt, Marit J. van Gils, Johannes B. van Goudoever, Britt J. van Keulen · 2021 · Journal of Human Lactation
18. Immune response to SARS‐CoV‐2 in children: A review of the current knowledge
    Filippos Filippatos, Elizabeth‐Barbara Tatsi, Athanasios G. Michos · 2021 · Pediatric Investigation
19. Immunopathology and Immunosenescence, the Immunological Key Words of Severe COVID-19. Is There a Role for Stem Cell Transplantation?
    Mattia Emanuela Ligotti, Fanny Pojero, Giulia Accardi, Anna Aiello, Calogero Caruso, Giovanni Duro, Giuseppina Candore · 2021 · Frontiers in Cell and Developmental Biology
20. What Happens to the Immune System after Vaccination or Recovery from COVID-19?
    Bruna Tiaki Tiyo, Gabriela J. H. Schmitz, Marina Mazzilli Ortega, Laís T. da Silva, Alexandre de Almeida, Telma Miyuki Oshiro, Alberto José da Silva Duarte · 2021 · Life
21. Rapid test to assess the escape of SARS-CoV-2 variants of concern
    Jacob T. Heggestad, Rhett J. Britton, David Kinnamon, Simone A. Wall, Daniel Y. Joh, Angus Hucknall, Lyra B. Olson, Jack G. Anderson, Anna Mazur, Cameron R. Wolfe et al. · 2021 · Science Advances
22. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters
    Yuki Takamatsu, Masaki Imai, Kenji Maeda, Noriko Nakajima, Nobuyo Higashi‐Kuwata, Kiyoko Iwatsuki‐Horimoto, Mutsumi Ito, Maki Kiso, Tadashi Maemura, Yuichiro Takeda et al. · 2021 · Journal of Virology
23. T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants
    Thi H. O. Nguyen, Carolyn A. Cohen, Louise C. Rowntree, Maireid B. Bull, Asmaa Hachim, Katherine Kedzierska, Sophie A. Valkenburg · 2021 · Frontiers in Medicine
24. A combined model for COVID-19 pandemic control: The application of Haddon's matrix and community risk reduction tools combined
    Anas A. Khan, Yasir S. Almuzaini, Alhanouf Aburas, Naif Khalaf Alharbi, Suliman Abdullah Alghnam, Jaffar A. Al‐Tawfiq, Ahmed Alahmari, ‏Yousef Alsofayan, Fahad Abdulrahman Alamri, Mohammed Ahmed Garout et al. · 2022 · Journal of Infection and Public Health
25. Post‐sequelae symptoms and comorbidities after COVID‐19
    Priya Duggal, Tristan Penson, Hannah N. Manley, Candelaria Vergara, Rebecca M. Munday, Dylan Duchen, Elizabeth A. Linton, Amber Zurn, Jeanne C. Keruly, Shruti H. Mehta et al. · 2022 · Journal of Medical Virology
26. SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort
    Emilie Finch, Rachel Lowe, Stephanie Fischinger, Michael de St. Aubin, Sameed M. Siddiqui, Diana Dayal, Michael A. Loesche, Justin Rhee, Samuel B. Beger, Yiyuan David Hu et al. · 2022 · PLoS Biology
27. Mean field game for modeling of COVID-19 spread
    Viktoriya Petrakova, Криворотько Ольга Игоревна · 2022 · Journal of Mathematical Analysis and Applications
28. How immunity from and interaction with seasonal coronaviruses can shape SARS-CoV-2 epidemiology
    Naomi R. Waterlow, Edwin van Leeuwen, Nicholas G. Davies, CMMID COVID-19 Working Group, Stefan Flasche, Rosalind M. Eggo · 2021 · Proceedings of the National Academy of Sciences
29. Immunization With Lipopolysaccharide-Activated Dendritic Cells Generates a Specific CD8+ T Cell Response That Confers Partial Protection Against Infection With Trypanosoma cruzi
    Lucía Biscari, Cintia Daniela Kaufman, Cecilia Farré, Victoria Huhn, María Florencia Pacini, Camila Bulfoni Balbi, Karina A. Gómez, Ana Rosa Pérez, Andrés Alloatti · 2022 · Frontiers in Cellular and Infection Microbiology
30. Antibody Levels Poorly Reflect on the Frequency of Memory B Cells Generated following SARS-CoV-2, Seasonal Influenza, or EBV Infection
    Carla Wolf, Sebastian Köppert, Noémi Becza, Stefanie Küerten, Greg A. Kirchenbaum, Paul Lehmann · 2022 · Cells
31. SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
    Raju Sunagar, Amit Singh, Sudeep Kumar · 2023 · Vaccines
32. SARS-CoV-2 infection and recovery in children: Distinct T cell responses in MIS-C compared to COVID-19
    Ksenia Rybkina, Joseph Bell, Marissa C. Bradley, Teddy John Wohlbold, Marika Scafuro, Wenzhao Meng, Rebecca C. Korenberg, Julia Davis‐Porada, Brett R. Anderson, Rachel J. Weller et al. · 2023 · The Journal of Experimental Medicine
33. Early and long term antibody kinetics of asymptomatic and mild disease COVID-19 patients
    Shai Efrati, Merav Catalogna, Ramzia Abu Hamed, Amir Hadanny, Adina Bar‐Chaim, Patricia Benveniste‐Levkovitz, Refael Strugo, Osnat Levtzion‐Korach · 2021 · Scientific Reports
34. Clinical Utility of SARS-CoV-2 Serological Testing and Defining a Correlate of Protection
    Kimia Sobhani, Susan C. Cheng, Raquel A. Binder, Nicholas John Mantis, James M. Crawford, Nkemakonam C. Okoye, Jonathan G. Braun, Sandy Y. Joung, Minhao Wang, Gerard Lozanski et al. · 2023 · Vaccines
35. Persistence of antibody response to SARS-CoV-2 in a cohort of haemodialysis patients with COVID-19
    Suzanne Helen Forbes, Maria Davari, Sahana Gnanasampanthan, Noam Pinchas Gessler Roth, Gregor Young, Ravindra Rajakariar, Andrea Cove‐Smith, Muhammed Magdi Yaqoob, Teresa Cutiño‐Moguel, Viyaasan Mahalingasivam et al. · 2021 · Nephrology Dialysis Transplantation
36. Antibody Responses One Year after Mild SARS-CoV-2 Infection
    Pyoeng Gyun Choe, Kye‐Hyung Kim, Chang Kyung Kang, Hyeon Jeong Suh, EunKyo Kang, Sun Young Lee, Nam Joong Kim, Jongyoun Yi, Wan Beom Park, Myoung‐don Oh · 2021 · Journal of Korean Medical Science
37. Assessing the impact of widespread respirator use in curtailing COVID-19 transmission in the USA
    Calistus N. Ngonghala, James R. Knitter, Lucas Marinacci, Matthew H. Bonds, Abba B. Gumel · 2021 · Royal Society Open Science
38. Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?
    Gaurav Joshi, Pobitra Borah, Shweta Thakur, Praveen Sharma, Mayank Mayank, Poduri Ramarao · 2021 · Human Vaccines & Immunotherapeutics
39. A novel multiplex electrochemiluminescent immunoassay for detection and quantification of anti-SARS-CoV-2 IgG and anti-seasonal endemic human coronavirus IgG
    Fang Fang Li, Aaron C. Liu, Ebrima Gibbs, Guadalein Tanunliong, Ana Citlali Marquez, Soren M. Gantt, Hans Frykman, Mel Krajden, Muhammad Golam Morshed, Natalie Prystajecky et al. · 2021 · Journal of Clinical Virology
40. Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi‐Ethnic Observational Study
    Ilya Kister, Y. Patskovsky, Ryan Curtin, Jinglan Pei, Katherine Perdomo, Zoe Rimler, Iryna Voloshyna, Marie I. Samanovic, Amber R. Cornelius, Yogambigai Velmurugu et al. · 2022 · Annals of Neurology
41. Structure of a Vaccine-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain
    Clara G. Altomare, Daniel C. Adelsberg, Juan Manuel Carreño, Iden A. Sapse, Fatima Amanat, Ali H. Ellebedy, Viviana R. Simon, Florian Krammer, Goran Bajic · 2022 · mBio
42. Antibody-mediated immunity to SARS-CoV-2 spike
    John M. Errico, Lucas J. Adams, Daved H. Fremont · 2022 · Advances in immunology
43. The striking mimics between COVID-19 and malaria: A review
    Emadeldin Hassan E. Konozy, Makarim Elfadil M. Osman, George Ghartey‐Kwansah, Hind Mohamed Abushama · 2022 · Frontiers in Immunology
44. Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles
    E. Touizer, Aljawharah Alrubayyi, R. Ford, N. Hussain, P. Gerber, Hiu-Long Shum, C. Rees-Spear, L. Muir, E. Gea-Mallorquí, J. Kopycinski et al. · 2022 · iScience
45. Prevalence and functional profile of SARS-CoV-2 T cells in asymptomatic Kenyan adults
    Taraz Samandari, Joshua Ongalo, Kimberly D. McCarthy, Richard Biegon, Philister Adhiambo Madiega, Anne Mithika, Joseph Orinda, Grace Mboya, Patrick Mwaura, Omu Aggrey Anzala et al. · 2023 · Journal of Clinical Investigation
46. Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review
    Maryam Arabi, Yousef A. Al-Najjar, Omna Sharma, I. Kamal, Aimen Javed, Harsh Gohil, Pradipta Paul, Aljazi M. Al-Khalifa, Sa’ad Laws, Dalia Zakaria · 2023 · BMC Infectious Diseases
47. Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-α-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formation
    Erika Garner‐Spitzer, Angelika Wagner, Venugopal Gudipati, Anna‐Margarita Schötta, Maria Orola-Taus, Michael Kundi, Renate Kunert, Patrick Mayrhofer, Johannes B. Huppa, Hannes S. J. Stockinger et al. · 2023 · EBioMedicine
48. Metasurface‐Driven and Nanomaterial‐Coupled Plasmonic Biosensor for the Rapid and Quantitative Clinical Identification of Neutralizing Antibodies against SARS‐CoV‐2 Variants
    Rui Li, Ya Zhao, Hongli Fan, Hanlin Zhou, Shaoping Yin, Qiang Zhang, Meilin Jin, Gang Logan Liu, Liping Huang · 2023 · Advanced Functional Materials
49. Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh
    Md. Ahsanul Haq, Anjan Kumar Roy, Razu Ahmed, Rakib Ullah Kuddusi, Monika Sinha, Md Shamim Hossain, Maya Vandenent, Mohammad Zahirul Islam, Rashid Uz Zaman, Md. Golam Kibria et al. · 2024 · Scientific Reports
50. Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays
    Jenni M. E. Virtanen, Ruut Uusitalo, Essi M. Korhonen, Kirsi Aaltonen, Teemu Smura, Suvi H. Kuivanen, Sari H. Pakkanen, Sointu Mero, Anu Patjas, Marianna Riekkinen et al. · 2021 · Viruses
51. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)
    Heinz Wiendl, Ralf Gold, Thomas Berger, Tobias J Derfuss, Ralf Andreas Linker, Mathias Mäurer, Martin Stangel, Orhan Aktaş, Karl Baum, Martin Berghoff et al. · 2021 · Der Nervenarzt
52. Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants
    Amin Addetia, Luca Piccoli, James Brett Case, Young‐Jun Park, Martina Beltramello, Barbara Guarino, Ha V. Dang, Dora Pinto, Suzanne M. Scheaffer, Kaitlin R. Sprouse et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
53. Heterogeneous magnitude of immunological memory to SARS‐CoV‐2 in recovered individuals
    Alessio Mazzoni, Laura Maggi, Manuela Capone, Anna Vanni, Michele Spinicci, Lorenzo Salvati, Seble Tekle Kiros, Roberto Semeraro, Luca Pengue, Maria Grazia Colao et al. · 2021 · Clinical & Translational Immunology
54. SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study
    Antoine Lewin, Roseline Therrien, Gaston De Serres, Yves Grégoire, Josée Perreault, Mathieu Drouin, Marie‐Josée Fournier, Tony Tremblay, Julie Beaudoin, Guillaume Beaudoin-Bussières et al. · 2021 · Canadian Journal of Public Health
55. An examination of school reopening strategies during the SARS-CoV-2 pandemic
    Alfonso Landeros, Xiang Ji, Kenneth L. Lange, Timothy C. Stutz, Jason Xu, Mary Elizabeth Sehl, Janet S. Sinsheimer · 2021 · PLoS ONE
56. A Cross-Sectional Analysis of Demographic and Behavioral Risk Factors of Severe Acute Respiratory Syndrome Coronavirus 2 Seropositivity Among a Sample of U.S. College Students
    Sina Kianersi, Christina Ludema, Jonathan T. Macy, Edlin Garcia Colato, Chen Chen, Maya C. Luetke, Mason H. Lown, Molly S. Rosenberg · 2021 · Journal of Adolescent Health
57. Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
    Chiara Rosa Mancinelli, Nicola De Rossi, Ruggero Capra · 2021 · Therapeutics and Clinical Risk Management
58. Low risk of reinfections and relation with serological response after recovery from the first wave of COVID-19
    Maddalena Peghin, Emilio Bouza, Martina Fabris, Maria De Martino, Alvisa Palese, Giulia Bontempo, Elena Graziano, Valentina Gerussi, Valentina Bressan, Assunta Sartor et al. · 2021 · European Journal of Clinical Microbiology & Infectious Diseases
59. SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
    Vimvara Vacharathit, Sirawat Srichatrapimuk, Suwimon Manopwisedjaroen, Suppachok Kirdlarp, Chanya Srisaowakarn, Chavachol Setthaudom, Nanthicha Inrueangsri, Prapaporn Pisitkun, Mongkol Kunakorn, Suradej Hongeng et al. · 2021 · International Journal of Infectious Diseases
60. Automated ELISA On-Chip for the Detection of Anti-SARS-CoV-2 Antibodies
    Everardo Gonzalez‐González, Ricardo Garcia-Ramirez, Gladys Guadalupe Díaz-Armas, Miguel Esparza, Carlos Aguilar-Avelar, Elda A. Flores-Contreras, Iram Pablo Rodriguez-Sanchez, Jesús Rolando Delgado-Balderas, Brenda Soto‐García, Diana Araíz-Hernández et al. · 2021 · Sensors
61. Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1β, Early Predictors of Severe COVID-19
    Helena Colom Codina, Irene Viéitez, Alicia Gutiérrez‐Valencia, Vasso Skouridou, Cristina Martínez, Lucía Patiño, Mariluz Botero-Gallego, María Trujillo‐Rodríguez, Ana Serna‐Gallego, Esperanza Muñoz‐Muela et al. · 2021 · Microorganisms
62. Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men
    Nina Le Bert, Wan Ni Chia, Wei Yee Wan, Alvin Kuo Jing Teo, Samuel Zeng Rong Chong, Nicole Tan, Doreen Soek Chin Tan, Adeline Chia, Iain Beehuat Tan, Kamini Kunasegaran et al. · 2021 · Emerging Microbes & Infections
63. SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients
    Michael Gurevich, Rina Zilkha‐Falb, Polina Sonis, David Magalashvili, Shay Menascu, Shlomo Flechter, Mark Dolev, Mathilda Mandel, Anat Achiron · 2021 · International Journal of Infectious Diseases
64. Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in older residents of a long-term care facility: relation with age, frailty and prior infection status
    Piotr Seiffert, Adam Konka, Janusz Kasperczyk, Jacek Kawa, Mateusz Lejawa, Barbara Maślanka-Seiffert, Joanna Zembala-John, Monika Natalia Bugdol, Małgorzata K. Romanik, Rafał Jakub Bułdak et al. · 2021 · Biogerontology
65. COVID‐19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations
    Marek Jutel, Marı́a José Torres, Óscar Palomares, Cezmi A. Akdiş, Thomas Eiwegger, Eva Untersmayr, Domingo Barber, Magdalena Zemelka‐Wiącek, Anna Kosowska, Elizabeth N. Palmer et al. · 2022 · Allergy
66. The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis
    Qi Chen, Kongxin Zhu, Xiaohui Liu, Chunlan Zhuang, Xingcheng Huang, Yue Huang, Xingmei Yao, Jiali Quan, Hongyan Lin, Shoujie Huang et al. · 2022 · Emerging Microbes & Infections
67. Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history
    Enrico Lavezzo, Monia Pacenti, Laura Manuto, Caterina Boldrin, Margherita Cattai, Marco Grazioli, Federico Bianca, Margherita Sartori, Federico Caldart, Gioele Castelli et al. · 2022 · Genome Medicine
68. Genomic surveillance, evolution and global transmission of SARS-CoV-2 during 2019–2022
    Nadim Sharif, Khalid Jamaan Alzahrani, Shamsun Nahar Ahmed, Afsana Khan, Hamsa Jameel Banjer, Fuad M. Alzahrani, Anowar Khasru Parvez, Shuvra Kanti Dey · 2022 · PLoS ONE
69. After the virus has cleared—Can preclinical models be employed for Long COVID research?
    Ethan B. Jansen, S. N. Orvold, C. Swan, Anthony Yourkowski, Brittany Thivierge, Magen E. Francis, Anni Ge, Melissa L. Rioux, Joseph Darbellay, J. Howland et al. · 2022 · PLoS Pathogens
70. Maternal Antibody Response and Transplacental Transfer Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection or Vaccination in Pregnancy
    Sebastián Otero, Emily Stinnett Miller, Ashwin Sunderraj, Elisheva D. Shanes, Allie Sakowicz, Jeffery A Goldstein, Leena Bhattacharya Mithal · 2022 · Clinical Infectious Diseases
71. mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection
    Ellie N. Ivanova, Jasmine Shwetar, Joseph Cooper Devlin, Terkild B. Buus, Sophie L. Gray-Gaillard, Akiko Koide, Amber R. Cornelius, Marie I. Samanovic, Alberto M. Herrera, Eleni P. Mimitou et al. · 2023 · iScience
72. Quantifying the role of naturally- and vaccine-derived neutralizing antibodies as a correlate of protection against COVID-19 variants
    Jamie A. Cohen, Robyn M. Stuart, Katherine Rosenfeld, Hil M. Lyons, Michael T. White, Cliff C. Kerr, Daniel J. Klein, Michael Famulare · 2021 · medRxiv
73. A Comprehensive Analysis of Structural and Functional Changes Induced by SARS-CoV-2 Spike Protein Mutations
    Aganze Gloire-Aimé Mushebenge, Samuel Chima Ugbaja, Nonkululeko Avril Mbatha, Rene Bernadette Khan, Hezekiel Mathambo Kumalo · 2023 · COVID
74. SARS-CoV-2 spike-specific nasal-resident CD49a+CD8+ memory T cells exert immediate effector functions with enhanced IFN-γ production
    Min‐Seok Rha, Gyeongyeob Kim, Sol Lee, Jihye Kim, Yeonsu Jeong, Chan Min Jung, Hae Eun Noh, Ji Yun Noh, Yong Min Kim, Hyung‐Ju Cho et al. · 2024 · Nature Communications
75. Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2
    Llipsy Santiago, Iratxe Uranga-Murillo, Maykel A. Arias, Andrés Manuel González‐Ramírez, Javier Macías‐León, Eduardo Moreo, Sergio Redrado, Ana García‐García, Víctor Taleb, Erandi Lira‐Navarrete et al. · 2021 · Biology
76. Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, Brazil
    Natalia Fintelman Rodrigues, Aline de Paula Dias da Silva, Monique Cristina dos Santos, Felipe Saraiva, Marcelo Alves Ferreira, João Silveira Moledo Gesto, Danielle A. S. Rodrigues, Andre Macedo Vale, Isaclaudia Gomes de Azevedo, Vinícius Cardoso Soares et al. · 2021 · Emerging infectious diseases
77. Immunity after SARS-CoV-2 infections
    Prasanna Jagannathan, Taia T. Wang · 2021 · Nature Immunology
78. Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
    Ahmet Soysal, Erdem Gönüllü, Nalan Karabayır, Servet Alan, Serkan Atıcı, İsmail Yıldız, Havva Engin, Mahmut Çivilibal, Metin Karaböcüoğlu · 2021 · Human Vaccines & Immunotherapeutics
79. SARS-CoV-2 Natural Antibody Response Persists for at Least 12 Months in a Nationwide Study From the Faroe Islands
    Maria Skaalum Petersen, Cecilie Bo Hansen, Marnar Fríðheim Kristiansen, Jógvan Páll Fjallsbak, Sólrun Larsen, Jóhanna Ljósá Hansen, Ida Jarlhelt, Laura Pérez‐Alós, Bjarni á Steig, Debes Hammershaimb Christiansen et al. · 2021 · Open Forum Infectious Diseases
80. Convalescent COVID-19 Patients Without Comorbidities Display Similar Immunophenotypes Over Time Despite Divergent Disease Severities
    Chang-Feng Chu, Florian Sabath, Silvia Fibi-Smetana, Shan Sun, Rupert Öllinger, Elfriede Noeßner, Ying-Yin Chao, Linus Rinke, Elena Winheim, Roland Rad et al. · 2021 · Frontiers in Immunology
81. Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals
    Sabrina Racine‐Brzostek, Jim K. Yee, Ashley C. Sukhu, Yuqing Qiu, Sophie Rand, Paul Dylan Barone, Ying Hao, He S. Yang, Qing H. Meng, Fred S. Apple et al. · 2021 · JCI Insight
82. COVID-19 Seroprevalence in Canada Modelling Waning and Boosting COVID-19 Immunity in Canada a Canadian Immunization Research Network Study
    David W. Dick, Lauren M. Childs, Zhilan Feng, Jing Li, Gergely Röst, David Llewellyn Buckeridge, Nicholas Hume Ogden, Jane Marie Heffernan · 2021 · Vaccines
83. Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods
    Jo‐Lewis Banga Ndzouboukou, Yandi Zhang, Xionglin Fan · 2021 · Current Medical Science
84. Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant
    Ruiqi Zhang, Ka-Wa Khong, Ka‐Yi Leung, Danlei Liu, Yujing Fan, Lu Lu, Pui-Chun Chan, Lin‐Lei Chen, Kelvin Kai‐Wang To, Honglin Chen et al. · 2021 · Vaccines
85. Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine
    Claudia Gandolfo, Gabriele Anichini, Marco Mugnaini, Monica Bocchia, Chiara Terrosi, Anna Sicuranza, Gianni Gori Savellini, Alessandro Gozzetti, Federico Franchi, Maria Grazia Cusi · 2022 · Vaccines
86. Cellular Immune Response after Vaccination in Patients with Cancer—Review on Past and Present Experiences
    Maria Madeleine Rüthrich, Nicola Giesen, Sibylle C. Mellinghoff, Christina Theresa Rieger, Marie von Lilienfeld‐Toal · 2022 · Vaccines
87. Decoupling of omicron variant infections and severe COVID-19
    Shabir Ahmed Madhi, Chikwe Ihekweazu, Helen Rees, Andrew John Pollard · 2022 · The Lancet
88. Multiplexed COVID-19 antibody quantification from human sera using label-free nanoplasmonic biosensors
    Wihan Adi, Dhruv Biswas, Miriam A. Shelef, Filiz Yesilköy · 2022 · Biomedical Optics Express
89. COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines
    B. Biswas, Shagnik Chattopadhyay, Sayantee Hazra, Arman Kunwar Hansda, R. Goswami · 2022 · Inflammation Research
90. Mouse models in COVID-19 research: analyzing the adaptive immune response
    S. Clever, A. Volz · 2022 · Medical Microbiology and Immmunology
91. Immune memory to SARS-CoV-2 Omicron BA.1 breakthrough infections: To change the vaccine or not?
    Menno C. van Zelm · 2022 · Science Immunology
92. Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes
    Rhiane Moody, Sabrina Sonda, Fay Helena Johnston, Kylie J. Smith, Nicola Stephens, Michelle McPherson, Katie L. Flanagan, Magdalena Plebanski · 2022 · Frontiers in Immunology
93. The immune response as a double‐edged sword: The lesson learnt during the COVID ‐19 pandemic
    Chiara Agrati, Rita Carsetti, Veronica Bordoni, Alessandra Sacchi, Concetta Quintarelli, Franco Locatelli, Giuseppe Ippolito, Maria Rosaria Capobianchi · 2022 · Immunology
94. Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population
    Protim Sarker, Evana Akhtar, Rakib Ullah Kuddusi, Mohammad Mamun Alam, Md. Ahsanul Haq, Md. Biplob Hosen, Bikash Chandra Chanda, Farjana Haque, Muntasir Alam, Abdur Razzaque et al. · 2022 · Vaccines
95. Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study
    Zicheng Hu, Kattria van der Ploeg, Saborni Chakraborty, Prabhu S. Arunachalam, Diego AM Mori, Karen Blake Jacobson, Hector Fabio Bonilla, Julie Parsonnet, Jason Randolph Andrews, Marisa K. Holubar et al. · 2022 · eLife
96. SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series
    Chapin S. Korosec, David W. Dick, Iain R. Moyles, James Watmough · 2024 · Scientific Reports
97. Human antiviral B cell responses: Emerging lessons from hepatitis B and COVID‐19
    Alice R. Burton, Mala K. Maini · 2021 · Immunological Reviews
98. Kinetics and biological characteristics of humoral response developing after SARS-CoV-2 infection: implications for vaccination
    Giuseppe Lippi, Laura Sciacovelli, Tommaso Trenti, Mario Plebani · 2021 · Clinical Chemistry and Laboratory Medicine (CCLM)
99. T-Cell Immune Responses to SARS-CoV-2 Infection and Vaccination
    Samuele Notarbartolo · 2024 · Vaccines
100. Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19–Convalescent Donors
     Bernd Jahrsdörfer, Rüdiger M. Groß, Alina Seidel, Lukas Wettstein, Carolin Ludwig, Tatjana Schwarz, Sixten Körper, Markus Rojewski, Ramin Lotfi, Christoph Weinstock et al. · 2021 · The Journal of Immunology